Markus Britschgi Selected Research

Therapeutics

1/2022	Trial of Prasinezumab in Early-Stage Parkinson's Disease.
1/2016	Combined Plasma and Cerebrospinal Fluid Signature for the Prediction of Midterm Progression From Mild Cognitive Impairment to Alzheimer Disease.
4/2013	Inflammation and α-synuclein's prion-like behavior in Parkinson's disease--is there a link?
11/2007	Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Markus Britschgi Research Topics

Disease

10	Parkinson Disease (Parkinson's Disease) 01/2022 - 04/2013
8	Alzheimer Disease (Alzheimer's Disease) 01/2017 - 11/2007
5	Inflammation (Inflammations) 01/2021 - 08/2002
3	Neuroinflammatory Diseases 01/2022 - 09/2012
3	Acute Generalized Exanthematous Pustulosis 12/2005 - 01/2002
2	Dementia (Dementias) 01/2022 - 01/2016
2	Synucleinopathies 01/2022 - 01/2018
2	Disease Progression 01/2021 - 04/2013
2	Cognitive Dysfunction 02/2009 - 11/2007
1	Multiple System Atrophy 01/2022
1	Colitis 01/2021
1	Hypokinesia (Bradykinesia) 01/2021
1	Movement Disorders (Movement Disorder) 01/2021
1	Tremor (Tremors) 01/2021
1	Prodromal Symptoms 01/2016
1	Gliosis 01/2013
1	Human Influenza (Influenza) 10/2012
1	Encephalitis (Encephalitis, Rasmussen) 10/2012
1	Tauopathies 09/2012
1	Amyloid Plaque 05/2012
1	Delayed Hypersensitivity (Hypersensitivity, Type IV) 06/2007
1	Psoriasis (Pustulosis Palmaris et Plantaris) 12/2005
1	Hypersensitivity (Allergy) 12/2002
1	Infections 08/2002
1	Drug Hypersensitivity (Drug Allergy) 01/2002

Drug/Important Bio-Agent (IBA)

7	Proteins (Proteins, Gene)FDA Link 01/2021 - 11/2007
6	alpha-SynucleinIBA 01/2022 - 01/2018
5	SynucleinsIBA 01/2022 - 04/2013
3	Amyloid (Amyloid Fibrils)IBA 01/2016 - 10/2011
2	CytokinesIBA 01/2022 - 10/2006
2	LipopolysaccharidesIBA 01/2022 - 01/2021
2	Serine (L-Serine)FDA Link 01/2021 - 01/2021
2	Complement System Proteins (Complement)IBA 01/2017 - 09/2012
2	Interleukin-8 (Interleukin 8)IBA 08/2002 - 01/2002
1	Detergents (Detergent)IBA 01/2022
1	AntibodiesIBA 01/2022
1	Monoclonal AntibodiesIBA 01/2022
1	Monoamine Oxidase (MAO)IBA 01/2021
1	Dextran SulfateIBA 01/2021
1	LipidsIBA 01/2019
1	PrionsIBA 04/2013
1	NeurotoxinsIBA 01/2013
1	Oseltamivir (Tamiflu)FDA Link 10/2012
1	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 09/2012
1	EpitopesIBA 05/2012
1	Peptides (Polypeptides)IBA 05/2012
1	Heparitin Sulfate (Heparan Sulfate)IBA 05/2012
1	ProteomeIBA 10/2011
1	Blood Proteins (Serum Proteins)IBA 02/2009
1	Beclin-1IBA 06/2008
1	Autophagy-Related ProteinsIBA 06/2008
1	Amyloid beta-PeptidesIBA 06/2008
1	5-(6)-carboxyfluorescein diacetate succinimidyl ester (CFSE)IBA 06/2007
1	ThymidineIBA 06/2007
1	Iohexol (Omnipaque)FDA Link 06/2007
1	iomeprolIBA 06/2007
1	Contrast MediaIBA 06/2007
1	Chemokine ReceptorsIBA 12/2005
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 12/2005
1	Interleukin-5 (Interleukin 5)IBA 12/2005
1	SulfonamidesIBA 12/2002
1	MercuryIBA 08/2002

Therapy/Procedure

4	Therapeutics 01/2022 - 11/2007